InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,160.00
(
-0.08%
)
Dow Jones
39,127.80
(
0.04%
)
Brent Oil
84.47
(
0.34%
)
Bitcoin
60,964.90
(
-1.37%
)
Post# of 77
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biotech_researcher

Send PM Follow Ignore
Followers 84
Posts 12467
Boards Moderated 0
Alias Born 07/25/2008

biotech_researcher

Re: None

Tuesday, 01/18/2022 8:51:01 AM

Tuesday, January 18, 2022 8:51:01 AM

Post# of 77
Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights
Jan 18, 2022

PDF Version
Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray for Acute Migraine Delivered Strong Q4 2021 Launch with 4,200 (TRx) Prescriptions; Exceeding Company’s Guidance Range

Achieved Broad and Favorable Trudhesa™ Payer Coverage with Signed Agreements Covering 80% of U.S. Commercial Lives

Planned Initiation of INP105 Proof-of-Concept Study for Autism Spectrum Disorder in Q1 2022; Results anticipated Q4 2022

https://investors.impelnp.com/news-releases/news-release-details/impel-neuropharma-provides-updates-trudhesatm-launch-and-recent/
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up